LONGEVA.

HGH Fragment 176-191: adverse events and evidence limits

The Longeva listing describes unmodified HGH Fragment 176-191 as a 5 mg lyophilized powder [1]. Its native sequence, FLRIVQCRSVEGSCGF, differs from AOD9604 (YLRIVQCRSVEGSCGF) at the first residue: phenylalanine instead of tyrosine [2][4]. This compares the named compounds and does not verify a particular batch.

The inspected 1978 primary abstract includes synthetic 176-191 among peptides causing a brief glucose rise and a longer insulin rise in normal rats. It also reports reduced insulin sensitivity after a single 5 nmol/kg exposure to active fragments. The abstract leaves peptide administration route unstated; its intravenous wording describes the insulin-tolerance test [3].

A separate report of intravenous and oral AOD9604 describes severe chest tightness and a serious adverse event, diarrhoea, as possibly treatment-related [4]. These concern another molecule and studied formulations. The inspected sources cannot estimate clinical adverse-reaction incidence or establish safety of the current native fragment; the exposure stated here is study context, not a recommendation [1][2][3][4].

What the studies reported

EffectModel or participantsHow often or as describedSource
Brief glucose riseNormal rats; synthetic C-terminal growth-hormone fragments, including 176-191Observed; a metabolic measurement in an animal model — no clinical frequency established[3]
Longer insulin rise and reduced insulin sensitivityThe same rats; reduced sensitivity after a single 5 nmol/kg exposure to active fragmentsObserved; hormonal measurements that provide no human clinical adverse-event frequencies[3]
Severe chest tightness; serious diarrhoeaHumans; AOD9604 (a different molecule), intravenous and oralDescribed as possibly treatment-related; these are data on another molecule, not the native 176-191 fragment, and establish no frequency for it[4]

References

  1. Longeva (2026). Public HGH Fragment 176-191 listing https://longeva.bio/ua/product/hgh-fragment-176-191.
  2. L. Chantalat; N. D. Jones; F. Korber; J. Navaza; A. G. Pavlovsky (1995). HUMAN GROWTH HORMONE; associated citation: The crystal-structure of wild-type growth-hormone at 2.5 Angstrom resolution. https://www.rcsb.org/structure/1HGU.
  3. F. M. Ng; J. Bornstein (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone https://pubmed.ncbi.nlm.nih.gov/645904/ doi:10.1152/ajpendo.1978.234.5.E521.
  4. Heike Stier; Evert Vos; David Kenley (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans https://jofem.org/index.php/jofem/article/view/157/194 doi:10.4021/jem157w.